版本:
中国

BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition

April 24 Xoma Corp

* Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition

* Xoma Corp says has achieved positive phase 2 proof-of-concept results for x213 in physiological hyperprolactinemia

* Xoma Corp - while study was not intended, or powered to show statistical significance, it demonstrated that X213 was safe and well tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐